Clinical and economic impact of ibalizumab for MDR cohorts Trogarzo may never reach the initial sale projection but as per CEO the drug is projected to have a %25 percent compounded growth in the next four years from very low current sale levels as it is currently the only drug which is still effective when other antiviral medication are failing due to viral cross resistance.
The article below was posted yesterday on JAIDS.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066538/
“We project that ibalizumab will substantially improve survival for people with MDR HIV. As with most biologics, the cost of ibalizumab is high, and thus ibalizumab is not cost-effective by general US criteria despite its clinical benefit. Nevertheless, for highly treatment-experienced people with MDR HIV who have limited treatment options and virologic failure, ibalizumab is currently the only available treatment that will improve survival. Given the small size of the US population that will benefit from ibalizumab, the total budget impact to payers will be low despite the high cost of the drug.”